Save Time. Save Minds.
Time is the most critical variable for neurological conditions. From the first sign of cognitive decline to the management of neurological diseases, every moment saved in the patient pathway is a moment gained for intervention.
At this year’s AAIC Congress in London, we are actively contributing to bring the most up-to-date diagnostic tools to the clinicians and their patients.
Experience the future of Alzheimer’s disease Diagnostics at the Roche booth #311
- Experience the pTau217 revolution: See how the Elecsys® pTau217p blood‑based assay is reshaping the Alzheimer’s disease patient pathway, helping support earlier and more accessible disease diagnosis.1
- Discover Elecsys® ApoE4 – a first-of-its-kind: Learn about this first IVD immunoassay blood test, which identifies carriers of ApoE4, eliminates the need for confirmatory genetic testing in a significant proportion of patients.2
- Explore one of the broadest portfolios in Alzheimer’s disease: From blood‑based assays (Elecsys® pTau217p, Elecsys® pTau181p, Elecsys® ApoE4) to CSF assays, digital solutions and RUO tests, discover how our portfolio supports more timely detection, diagnosis and monitoring across the care pathway.
Meet the speakers
Chairperson: Prof. Alicia Algeciras Schimnich
Professor of Laboratory Medicine and Pathology at Mayo Clinic Rochester
Rochester, Minnesota, United States
Speaker: Prof. Craig Ritchie
MBChB PhD MSc FRCP(Edin) MRCPsych
CEO and Founder: Scottish Brain Sciences
Professor of Brain Health and Neurodegenerative Medicine: University of St Andrews.
Edinburgh, UK
Speaker: Prof. Nick Ashton
Senior Director Fluid Biomarker program at Banner Sun Health Research Institute
Sun City, Arizona, United States
References
- F. Hoffmann-La Roche Ltd. Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217) [Internet; cited 2026 May 19]. Available from: https://www.roche.com/media/releases/med-cor-2026-05-12.
- F. Hoffmann-La Roche Ltd. Roche receives CE mark for the first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer’s disease [Internet; cited 2026 May 19]. Available from: https://diagnostics.roche.com/global/en/news-listing/2026/roche-ce-mark-apoe4.html.